Embolism and Thrombosis
24
4
5
14
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.2%
1 terminated out of 24 trials
93.3%
+6.8% vs benchmark
8%
2 trials in Phase 3/4
21%
3 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (24)
The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry
Collection of Blood Samples for New Diagnostic Devices 2
Aventus Thrombectomy System Pulmonary Embolism Clinical Study
Safety and Efficiency of the YEARS Algorithm Versus Computed Tomography Pulmonary Angiography Alone for Suspected Pulmonary Embolism in Patients With Malignancy
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism
Prolonged Anticoagulation Therapy on the Prognosis of Patients With Left Ventricular Thrombosis
Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests
Observational Dutch Young Symptomatic StrokE studY - nEXT
Risk Stratification for Venous Thromboembolism in Hospitalized Medical Patients
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
Medical Assistance for the Procreation and Risk of Thrombosis.
COVID-19, bLOod Coagulation and Thrombosis
Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
Platelet Activity in Vascular Surgery for Thrombosis and Bleeding
Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs
The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis
Comparison of Accidents and Their Circumstances With Oral Anticoagulants
Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants